Literature DB >> 10195199

Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1.

A G Schuller1, M A King, J Zhang, E Bolan, Y X Pan, D J Morgan, A Chang, M E Czick, E M Unterwald, G W Pasternak, J E Pintar.   

Abstract

Morphine produces analgesia by activating mu opioid receptors encoded by the MOR-1 gene. Although morphine-6 beta-glucuronide (M6G), heroin and 6-acetylmorphine also are considered mu opioids, recent evidence suggests that they act through a distinct receptor mechanism. We examined this question in knockout mice containing disruptions of either the first or second coding exon of MOR-1. Mice homozygous for either MOR-1 mutation were insensitive to morphine. Heroin, 6-acetylmorphine and M6G still elicited analgesia in the exon-1 MOR-1 mutant, which also showed specific M6G binding, whereas M6G and 6-acetylmorphine were inactive in the exon-2 MOR-1 mutant. These results provide genetic evidence for a unique receptor site for M6G and heroin analgesia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195199     DOI: 10.1038/5706

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  99 in total

1.  Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene.

Authors:  Y X Pan; J Xu; L Mahurter; E Bolan; M Xu; G W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling.

Authors:  Erica J Melief; Mayumi Miyatake; Michael R Bruchas; Charles Chavkin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-03       Impact factor: 11.205

3.  Morphine-6 beta-glucuronide has a higher efficacy than morphine as a mu-opioid receptor agonist in the rat locus coeruleus.

Authors:  P B Osborne; B Chieng; M J Christie
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 4.  mRNA transcript diversity creates new opportunities for pharmacological intervention.

Authors:  Elizabeth S Barrie; Ryan M Smith; Jonathan C Sanford; Wolfgang Sadee
Journal:  Mol Pharmacol       Date:  2012-02-07       Impact factor: 4.436

5.  Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands.

Authors:  Michael A Ansonoff; Philip S Portoghese; John E Pintar
Journal:  Psychopharmacology (Berl)       Date:  2010-03-24       Impact factor: 4.530

6.  Splice variation of the mu-opioid receptor and its effect on the action of opioids.

Authors:  Sophy K Gretton; Joanne Droney
Journal:  Br J Pain       Date:  2014-11

7.  Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia.

Authors:  L Gendron; J E Pintar; C Chavkin
Journal:  Neuroscience       Date:  2007-10-05       Impact factor: 3.590

8.  Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene.

Authors:  Jin Xu; Mingming Xu; Yasmin L Hurd; Gavril W Pasternak; Ying-Xian Pan
Journal:  J Neurochem       Date:  2008-12-10       Impact factor: 5.372

Review 9.  μ-Opioid receptor 6-transmembrane isoform: A potential therapeutic target for new effective opioids.

Authors:  Marino Convertino; Alexander Samoshkin; Josee Gauthier; Michael S Gold; William Maixner; Nikolay V Dokholyan; Luda Diatchenko
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-12-06       Impact factor: 5.067

10.  Brain region-specific N-glycosylation and lipid rafts association of the rat mu opioid receptor.

Authors:  Peng Huang; Chongguang Chen; Wei Xu; Su-In Yoon; Ellen M Unterwald; John E Pintar; Yulin Wang; Parkson Lee-Gau Chong; Lee-Yuan Liu-Chen
Journal:  Biochem Biophys Res Commun       Date:  2007-10-31       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.